Sequential [¹⁸F]FDG-[¹⁸F]FMISO PET and Multiparametric MRI at 3T for Insights into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience

Table 1

Summary of clinical data, immunohistochemical (IHC) status, and molecular pathology derived via IHC and clinical endpoints for all patients.

ID	Age	Histo	Grade	ER	PR	Her2	Ki67 (%)	Disease-specific death	Metastases
1	55	IDC	3	Negative	Negative	Negative	70	Y	Y
2	32	IDC	3	Negative	Negative	Negative	70	Y	Y
3	46	IDC	2	Positive	Positive	Negative	20	N	Y
4	68	IDC	3	Negative	Negative	Negative	90	Y	Y
5	36	IDC	3	Positive	Negative	Negative	80	N	Y
6	54	IDC	3	Negative	Negative	Positive	90	Y	Y
7	54	IDC	3	Positive	Positive	Negative	20	Y	Y
8	68	IDC	3	Positive	Negative	Negative	30	N	N
9	44	IDC	2	Positive	Positive	Negative	30	N	N
10	75	IDC	3	Negative	Negative	Negative	90	N	Y

ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2; Histo, histologic subtype; Ki67, proliferation rate; IDC, invasive ductal carcinoma.